屋尘螨过敏疫苗(Allergopharma)(House dust mite allergy vaccine(Allergopharma GmbH & Co. KG)) - 在研适应症：哮喘，变应性结膜炎，过敏性鼻炎_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名

Acaroid、Dermatophagoides pteronyssinus allergoids、House dust mite allergy vaccine

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病感染眼部疾病+ [2]

在研适应症

哮喘变应性结膜炎过敏性鼻炎

非在研适应症-

原研机构

Allergopharma GmbH & Co. KG

在研机构

Allergopharma GmbH & Co. KG

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与屋尘螨过敏疫苗(Allergopharma) 相关的临床试验

NCT03388359 / Unknown statusN/AIIT

Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma

Asthma is a major noncommunicable chronic inflammatory disorder which is characterized by airway inflammation and related to pathological modifications of the bronchial wall structure so called airway remodeling. Airway remodeling seen in asthma is mainly described by epithelial changes, subepithelial fibrosis, increased airway smooth muscle (ASM) mass, decreased distance between ASM and epithelium, mucous gland and goblet cell hyperplasia, vascular changes and edema. Near these well known pathophysiological changes of the airways, the extracellular matrix (ECM) can be distinguished as a new important factor included in development of airway remodeling in asthma.

开始日期2017-06-01

申办/合作机构

Lithuanian University of Health Sciences

[+1]

ChiCTR-IOR-17011067 / SuspendedIIT

Chinese Medicine Combined with Standardized House Dust Mite Vaccine Therapy on Allergic Asthmatic Children: A Preliminary Effect and Safety Aassessment

开始日期2017-05-01

申办/合作机构

云南省中医医院

NCT00540631 / Completed临床3期

A Multicentre Randomized Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of a Specific Immunotherapy With an Aluminium Hydroxide-adsorbed Allergoid Preparation of House Dust Mite (Dermatophagoides Pteronyssinus) in Patients With Rhinitis/Rhinoconjunctivitis and/or Allergic Asthma Bronchiale

Multicenter Immunotherapy House Dust Mite Allergoid

开始日期2007-10-01

申办/合作机构

Allergopharma GmbH & Co. KG

100 项与屋尘螨过敏疫苗(Allergopharma) 相关的临床结果

登录后查看更多信息

100 项与屋尘螨过敏疫苗(Allergopharma) 相关的转化医学

登录后查看更多信息

100 项与屋尘螨过敏疫苗(Allergopharma) 相关的专利（医药）

登录后查看更多信息

23

项与屋尘螨过敏疫苗(Allergopharma) 相关的文献（医药）

2019-07-01·Immunobiology4区 · 医学

Synergistic effect of Dermatophagoides pteronyssinus allergens and dexamethasone on the expression of CD163 by peripheral blood mononuclear cells

4区 · 医学

Article

作者: Bielecki, Paweł ; Sacharzewska, Ewa ; Golec, Paweł ; Kowal, Krzysztof ; Bernatowicz, Paweł Leszek ; Szczesiul, Michał ; Pampuch, Agnieszka

BACKGROUNDThe CD163 is a marker of monocyte/macrophage anti-inflammatory function. Its soluble form (sCD163) also exert anti-inflammatory activities including inhibition of T cell proliferation.OBJECTIVETo evaluate the effect of dexamethasone (Dx) and Dermatophagoides pteronyssinus (Dp) on ex vivo production of sCD163 by peripheral blood mononuclear cells (PBMCs).METHODSPBMCs from 26 allergic asthma patients (AAs) and 12 non-atopic healthy controls (HCs) were cultured with Dp, Dx, Dp + Dx or without any stimulation for up to 144 h (T₁₄₄). Concentration of sCD163, interleukin (IL) -6 and IL-10 in PMBC culture supernatants was evaluated using ELISA. The mRNA expression of CD163 by PBMCs was estimated using quantitative PCR (qPCR).RESULTSAt T₁₄₄ the median concentration of CD163 in unstimulated PBMC cultures of AAs was greater than that in HCs (p = 0.008). Concomitant application of Dp and Dx resulted in a synergistic effect reflected by a dramatic increase of sCD163 concentration both in HCs (p = 0.0002) and AAs (p < 0.0001). Also a synergistic effect of Dp and Dx on CD163 mRNA expression was seen at T₂₄ and T₄₈ but not at T₆ or T₁₂. Among asthmatic patients the effect of Dx on sCD163 production was attenuated in severe in comparison to mild-to-moderate AAs (p = 0.0007). Moreover, Dp-induced production of IL-6 but not IL-10 was inhibited by Dx (p < 0.0001). Inhibition of IL-10 decreased sCD163 concentration by more than 50%.CONCLUSIONSDx-triggered upregulation of anti-inflammatory CD163 expression by monocytes is synergistic with endogenous mechanisms involved in the resolution of Dp-induced inflammation. This effect is impaired in severe asthma patients.

2019-03-01·The Journal of Laryngology & Otology4区 · 医学

The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study

4区 · 医学

Article

作者: Zhang, H ; Jin, P ; Zhi, L ; Zi, X ; Zhao, L ; Tu, Y ; Shi, L ; Li, T

AbstractBackgroundSubcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.MethodA total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.ResultsAfter two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.ConclusionTwo-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.

2017-05-01·European annals of allergy and clinical immunology

Perceived efficacy and satisfaction of patients with subcutaneous hypoallergenic high-dose house dust mite extract.

Article

作者: Cancelliere, N ; López Abad, R ; Roger Reig, A ; Ibero Iborra, M ; Álvarez Nieto, J ; Carrillo Díaz, T ; Sánchez Moreno, V

SUMMARYThe efficacy and safety of subcutaneous immunotherapy with modified, high-dose, major allergen house dust mite extract is widely supported by double-blind, placebo-controlled studies. However, little is known regarding patient-perceived efficacy and satisfaction. An observational, retrospective, multicentre study in patients treated with Acaroid^® was conducted to assess the efficacy and degree of satisfaction of the patients after the first six months of treatment with it. All the clinical study procedures were performed according to the routine clinical practice. This study demonstrates that Acaroid^® is effective and well tolerated. The patients' condition demonstrated a clear and marked improvement in the first 6 months after treatment initiation. Patients treated with Acaroid^® were very satisfied, with a correlation to improvement in patient-perceived symptoms and the administration of treatment by a healthcare professional.

100 项与屋尘螨过敏疫苗(Allergopharma) 相关的药物交易

登录后查看更多信息